Soaring Demand Set to Propel Non-invasive Prenatal Testing Market to $10.86 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Non-invasive Prenatal Testing Market Through 2025?
The sphere of non-invasive prenatal testing has experienced swift expansion lately, projecting a rise from its current valuation of $5.48 billion in 2024 to an estimated $6.27 billion the following year, which reflects a compound annual growth rate of 14.5%; this historical upward trajectory owes its existence to factors like heightened diagnostic precision, diminished inherent dangers, the advancing age of expectant mothers, greater public knowledge, and official clinical recommendations.

What's the Projected Size of the Global Non-invasive Prenatal Testing Market by 2029?
Anticipation suggests the non-invasive prenatal testing market will experience accelerated expansion over the coming years, reaching a valuation of $10.86 billion by 2029, driven by a compound annual growth rate (CAGR) of 14.7%. This upward trajectory throughout the projection timeframe stems from several factors, including the broadening array of available tests, increased ease of access, the trend of later childbearing ages, enhanced capability to detect fetal abnormalities, and the integration of telemedicine and digital health solutions. Key developments shaping the market outlook forecast involve the introduction of broader test panels, greater uptake of NIPT procedures, continuous technological evolution, and advancements in non-invasive fetal aneuploidy diagnosis (NIFAD).

View the full report here:
https://www.thebusinessresearchcompany.com/report/non-invasive-prenatal-testing-global-market-report

Top Growth Drivers in the Non-invasive Prenatal Testing Industry: What's Accelerating the Market?
The elevated frequency of Down syndrome stands as a primary propellant for the non-invasive prenatal testing (NIPT) market, intensified by the trend of rising average maternal age, which consequently heightens anxieties regarding fetal development safety. This chromosomal abnormality, stemming from a cell division mistake that yields an additional chromosome 21, impacts both the cognitive functioning and physical maturation of the unborn child. Because NIPT screenings are entirely external to the body, they pose zero threat to the mother or the fetus, eschewing miscarriage risks associated with invasive procedures, and possess an accuracy exceeding 99 percent in identifying Down syndrome cases. Data from the National Down Syndrome Society and the Centres for Disease Control and Prevention indicates that in the United States, this condition affects approximately one in every 700 newborns, with a notable eighty percent of those diagnoses occurring in infants born to older mothers, thus the elevated probability of affected pregnancies in older women strongly encourages the expansion of the NIPT sector.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2492&type=smp

What Trends Will Shape the Non-invasive Prenatal Testing Market Through 2029 and Beyond?
The advent of next-generation sequencing has brought about significant improvements in throughput, scalability, and overall speed, subsequently empowering scientists to conduct diverse applications and investigate biological systems with greater depth. This technology functions as a platform facilitating the parallel sequencing of thousands to millions of DNA strands at once. Key industry players have rolled out this innovation with the goal of cutting down on both the temporal and financial investments while refining the process for generating outcomes related to genomic information and DNA analysis. Leading corporations, including Illumina, Eurofins, Natera, Roche, and Annoroad, have successfully integrated this sequencing methodology into non-invasive prenatal testing protocols. Marking a regulatory milestone, the CFDA, or China Food and Drug Administration, officially cleared the medical instrument product registration for the NGS instrument known as NextSeq 550AR, which is manufactured by Annoroad.

What Are the Main Segments in the Non-invasive Prenatal Testing Market?
The non-invasive prenatal testingmarket covered in this report is segmented -

1) By Type: Consumables; Instruments
2) By Application: Trisomy; Microdeletion; Genetics; Rh factor
3) By End User: Hospital; Diagnostic Labs

Subsegments:
1) By Consumables: Assay Kits; Reagents; Disposables
2) By Instruments: Next-Generation Sequencers (NGS); Polymerase Chain Reaction (PCR) Systems; Ultrasound Devices; Others (Microarrays And Mass Spectrometers)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=2492&type=smp

Which Top Companies are Driving Growth in the Non-invasive Prenatal Testing Market?
Major companies operating in the non-invasive prenatal testing market include F. Hoffmann-La Roche AG, Illumina Inc., Laboratory Corporation of America Holdings, Natera Inc., PerkinElmer Inc., Quest Diagnostics Inc., Agilent Technologies Inc., BGI Diagnosis Co Ltd., Berry Genomics Co, LifeCodexx AG, Myriad Genetics Inc., NIPD Genetics Co Ltd., Sequenom Inc., Annoroad Gene Technology Co Ltd., Centogene AG, Counsyl Inc., EUROFINS Genoma Group, Eurofins Scientific SE, Next Biosciences, Premaitha Health Plc, Ariosa Diagnostics Inc., Beijing Genomics Institute, Yourgene Health PLC, GE Healthcare Technologies Inc., Koninklijke Philips NV, Thermo Fisher Scientific Inc., Pacific Biosciences of California Inc., QIAGEN NV, MedGenome Labs Ltd., Progenity Inc.

Which Regions Will Dominate the Non-invasive Prenatal Testing Market Through 2029?
North America was the largest region in the non-invasive prenatal testing market in 2024. Western Europe was the second largest region in the non-invasive prenatal testing market. The regions covered in the non-invasive prenatal testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2492

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.